![]() ![]() |
![]() |
![]() |
Conference Details : Topics |
Register Online |
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
Overview
More than 20 million people are affected by diabetes and of this population nearly 65% will suffer early cardiovascular death. To effectively treat diabetes and reduce the risk of a cardiovascular event, glucose levels must be monitored and quickly controlled through changes in intervention, as outlined by the ADA/EASD treatment algorithm. Recent data provided by the National Health and Nutrition Examination Surveys (NHANES) revealed that there is some overall improvement in reaching the appropriate treatment standards, however, with the number of diabetes cases increasing by 1.5 million each year and the recent labeling changes affecting therapeutic options, it is more important than ever to be familiar with the pharmacologic treatment options for type 2 diabetes and the associated cardiovascular risk.
Objectives
Identify the current goals for A1C, blood pressure, and lipid levels set forth by the American Diabetes Association and apply them to the treatment strategies listed on the ADA/EASD algorithm in an effort to choose the best therapeutic option for each individual patient
Assess when patients with type 2 diabetes require cardiovascular risk reduction in addition to glycemic control and develop evidence-based approaches to treatment based on the ADA/EASD algorithm by reviewing adverse events
Faculty
Vivian A. Fonseca, MD, FRCP
Professor of Medicine and Pharmacology
Director, Diabetes Program
Tullis-Tulane Alumni Chair in Diabetes
Tulane University Health Sciences Center
New Orleans, LA
Mandeep Bajaj, MD
Associate Professor
Division of Diabetes, Endocrinology & Metabolism and
Molecular & Cellular Biology
Baylor College of Medicine
Houston, TX
Overview
The current use of lipid lowering therapy in clinical practice has fallen short of the recommendations of national guidelines. Clearly, not an easy venture when treating patients with dyslipidemia, many with multiple risk factors and many with resulting coronary events that may be preventable if patients were treated aggressively to meet the NCEP-ATP lll goals. This presentation will address the clinical challenges of goal attainment (lack of compliance, aggressive treatment by clinicians, not leaving patients 15 points from goals), and provide clinicians with the pathways and knowledge to help attain their patients to goal.
Objectives
Describe at least two challenges in treating dyslipidemia to NCEP-ATP III goals, implement strategies that will help to assess CHD risk accurately, and get patients to targeted goals
Identify patients at increased risk for cardiovascular events and develop a treatment plan with at least 2 lipid lowering strategies, including the use of multiple therapies, which will help these patients achieve guideline-based targets taking into consideration current lifestyle and pharmacologic treatment options available thus reducing overall cardiovascular risk
Faculty
James de Lemos, MD
Associate Professor of Medicine
J. Fred Schoelkopf Chair in Cardiology Research
Coronary Care Unit Director
UT Southwestern Medical Center
Dallas, TX
John Russell, MD
Clinical Associate Professor of Family and Community Medicine
Temple University School of Medicine
Philadelphia, PA
Overview
This program will address the need for improved communication between the clinician and the patient in the area of sexual health, providing communication techniques for the clinician to overcome the barriers that occur with discussing this issue with patients. In addition, the program will provide treatment options for preventing genital atrophy and enhancing libido.
Objectives
Develop communication skills that will improve discussions of sexual health issues with patients
Define the types of female sexual dysfunction including the role of estrogen deficiency in genital atrophy
Faculty
Murray A. Freedman, MS, MD
Clinical Professor, Department of Obstetrics and Gynecology
Medical College of Georgia
Augusta, GA
Overview
Despite a high prevalence in the United States, insomnia remains underdiagnosed and undertreated. Extensive research has identified several factors that contribute to the inadequate treatment of insomnia, including the failure of patients to report insomnia to clinicians and clinician misperceptions about the risks associated with hypnotic medications. This program will address effective strategies for diagnosing and treating patients with insomnia.
Objectives
Identify risk factors, determine appropriate screening tools, and accurately diagnose insomnia
Evaluate current and emerging nonpharmacologic and pharmacologic therapies for acute and chronic insomnia on the basis of efficacy and safety and apply this knowledge/skill with patients
Faculty
Paul Doghramji, MD, FAAFP
David Neubauer, MD
Johns Hopkins Sleep Disorder Center
Parkton, MD
Overview
Chronic Constipation is a multi-symptom gastrointestinal motility disorder that negatively impacts the lives of approximately 33 million Americans. Due to the overlap in symptoms reported by patients with irritable bowel syndrome-constipation and chronic constipation, clinicians often find it challenging to differentiate between the two. With a changing landscape of therapeutic options available, it is imperative that clinicians be able to establish and accurate diagnosis so the proper foundation is provided for determining initial therapy and developing a treatment plan.
Objectives
Differentiate chronic constipation from other functional bowel disorders
Identify the therapies that can be used to treat chronic constipation and other functional bowel disorders
Faculty
Lawrence R. Schiller, MD, FACP, FACG
Program Director
Gastroenterology Fellowship
Baylor University Medical Center
Dallas, TX
Louis Kuritzky, MD
Clinical Assistant Professor
Dept. of Community Health & Family Medicine
University of Florida
Gainesville, FL
Overview
Eyesight is a gift that most patients take for granted, until their vision becomes acutely compromised. When that happens, patients often present first to their primary care clinician. Because of the lack of formal ophthalmology training, many primary care clinicians feel uncomfortable in managing patients with eye disease. This program will help primary care clinicians recognize eye emergencies by reviewing the signs and symptoms of 10 important conditions which may restore the patientŐs eyesight and perhaps save their life.
Objectives
Identify at least 2 eye emergencies that can cause rapid blindness or threaten life if not properly diagnosed in the primary care setting
Diagnose age-related macular degeneration, diabetic retinopathy, glaucoma, and optic nerve disease in the primary care setting and refer patients at risk to ophthalmology
Faculty
Tommy Korn, MD, FACS
Attending Ophthalmologist, Sharp Memorial Hospital
Sharp Rees-Stealy Medical Group
San Diego, CA
Overview
Symptomatic treatment for menopausal women balances findings from clinical trials, guidelines, practice recommendations, and patient beliefs. Together clinicians will evaluate data and recommend initial treatment and follow up to meet a patient's needs for symptom management.
Objectives
Proactively assess and address menopausal issues with appropriate patients using clinician and patient education resources to improve communication and management of menopausal issues
Consistently apply with confidence the best evidence and up-to-date expert consensus recommendations to the clinical care and peri and menopausal patient
Faculty